Therefore, the FDA Fast Track Designation was granted to repotrectinib for the treatment of NSCLC patients bearing ROS1 rearrangements who have progressed on one ROS1 TKI and a platinum-doublet chemotherapy [35]. Here, ROS1 is linked to non-small cell lung carcinoma.